[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 5 sources · 18 days · First seen · Last updated

Regulatory penalties for Vietnamese pharmaceutical companies

Overview

Vietnamese pharmaceutical companies have faced regulatory penalties for financial and pricing violations.

In early September 2026, Vidipha Pharmaceutical Joint Stock Company (VDP) was ordered by the Ho Chi Minh City Tax Department to pay 812.5 million VND in tax arrears, penalties, and late payment interest. This regulatory action occurred alongside changes in the company’s shareholder structure, including the divestment of Chairman Kieu Huu’s 7.5% stake and the emergence of new major shareholders.

Later in the month, Dat Vi Phu Pharmaceutical Joint Stock Company was fined 25 million VND by the Drug Administration of Vietnam. The fine was issued for incorrect price declarations regarding the essential medicine Ozzy40, violating regulations under Decree 87/2024/ND-CP. The company was mandated to rectify its price declarations within 10 days to avoid compulsory enforcement.

Entities

Ministry of Health · Dat Vi Phu Pharmaceutical Joint Stock Company · Ho Chi Minh City · Vidipha Pharmaceutical Joint Stock Company · Ho Chi Minh City Tax Department

Timeline

  1. [BUSINESS] 4 sources
    Dat Vi Phu Pharmaceutical fined for incorrect drug pricing

    Dat Vi Phu Pharmaceutical Joint Stock Company was fined 25 million VND by Vietnam's Drug Administration for misreporting the selling price of the essential medicine Ozzy40.

  2. [BUSINESS] 2 sources
    Vidipha Pharmaceutical fined 812.5 million VND for tax violations

    Vidipha Pharmaceutical JSC must pay 812.5 million VND in tax arrears and penalties following a decision by the Ho Chi Minh City Tax Department.

Sources

cafebiz.vn · cafef.vn · kenh14.vn · kienthuc.net.vn · soha.vn